Evicenter
P&T meetings

QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Regulatory submission
NDA submitted August 2026
Last updated
78 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Microcystic lymphatic malformations

Economic impact of Microcystic lymphatic malformations on families

1 evidence topic · 1 source

Quantified family out-of-pocket costs and productivity losses

No evidence found.